Sol-Gel Technologies (SLGL) Non Operating Income (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Non Operating Income of -$128000.0 for Q1 2026, up 50.96% year-over-year from -$84791.9 in Q1 2025, and down 130.19% quarter-over-quarter from $424000.0 in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Non Operating Income (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Non Operating Income for 9 consecutive years, with -$128000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 50.96% year-over-year to -$128000.0; the TTM figure through Mar 2026 stood at $1.0 million (up 26.8% YoY), while the FY2025 annual figure was $1.4 million, down 1.6% from the prior year.
- Non Operating Income retreated to -$128000.0 in Q1 2026 per SLGL's latest filing, from $424000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $596000.0 in Q3 2023 and bottomed at -$368000.0 in Q1 2024.
- Historically, Non Operating Income has averaged $164588.2 across 5 years, with a median of $346000.0 in 2025.
- On a YoY basis, Non Operating Income climbed as much as 1457.14% in 2022 and fell as far as 3555.56% in 2022.
- Sol-Gel Technologies' Non Operating Income stood at $420000.0 in 2022, then soared by 35.95% to $571000.0 in 2023, then plunged by 55.69% to $253000.0 in 2024, then jumped by 67.59% to $424000.0 in 2025, then plunged by 130.19% to -$128000.0 in 2026.
- Business Quant data shows SLGL's Non Operating Income at -$128000.0 in Q1 2026, $424000.0 in Q4 2025, and $346000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 481,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 481,000.00 |
| Mar 31, 2026 | -128,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 346,000.00 |
| Jun 30, 2025 | 380,000.00 |
| Mar 31, 2025 | -261,000.00 |
| Dec 31, 2024 | 253,000.00 |
| Sep 30, 2024 | 462,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Mar 31, 2024 | -368,000.00 |
| Dec 31, 2023 | 571,000.00 |
| Sep 30, 2023 | 596,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Mar 31, 2023 | -342,000.00 |
| Dec 31, 2022 | 420,000.00 |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | -329,000.00 |
| Mar 31, 2022 | -353,000.00 |
| Dec 31, 2021 | 73,000.00 |
| Sep 30, 2021 | 14,000.00 |